Drug Profile
Deferasirox - Novartis
Alternative Names: CGP-72670; Deferasirox; Exjade; ICL-670; ICL-670A; JadenuLatest Information Update: 01 Feb 2024
Price :
$50
*
At a glance
- Originator Novartis
- Developer Novartis; University Hospital Grenoble
- Class Antianaemics; Benzoic acids; Small molecules; Triazoles
- Mechanism of Action Chelating agents; Cytochrome P 450 cyp2c8 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Iron overload
- Phase II Myelodysplastic syndromes; Thalassaemia
- Discontinued Malaria
Most Recent Events
- 15 Jan 2024 Novartis completes a phase II trial in Iron overload (In adolescents, In children) in Turkey, Tunisia, Thailand, Russia, Philippines, Panama, Oman, Malaysia, Lebanon, Italy, India, Hungary, France, Egypt, Bulgaria, Belgium, USA (PO, Granules) (NCT02435212) (EudraCT2013-004739-55)
- 17 Apr 2023 Novartis completes a phase II trial in Iron overload inFrance, Romania, Russia, Slovakia, Germany, Switzerland, and Spain (PO) (NCT03203850) (EudraCT2016-002529-12)
- 11 Mar 2021 Novartis completes the phase II JUPITER trial for Thalassaemia (In children, In the elderly, In adolescents, In adults, In infants) in Vietnam, Thailand, Saudi Arabia, Morocco, Lebanon, Turkey and Egypt (PO) (NCT02993224)